Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

Open access
Kuzmina, Alona, Khalaila, Yara, Voloshin, Olga, Keren-Naus, Ayelet, Boehm-Cohen, Liora, Raviv, Yael, Shemer-Avni, Yonat, Rosenberg, Elli, Taube, Ran·2021·Cell Host & Microbe

Published version of a preprint

Abstract

Toward eradicating the COVID-19 pandemic, vaccines that induce high humoral and cellular immune responses are essential. However, SARS-CoV-2 variants have begun to emerge and raise concerns, as they may potentially compromise vaccine efficiency. Here, we monitored neutralization potency of convalescent or Pfizer-BTN162b2 post-vaccination sera against pseudoviruses displaying spike proteins derived from wild-type SARS-CoV-2, or its UK-B.1.1.7 and SA-B.1.351 variants. Compared to convalescent sera, vaccination induces high titers of neutralizing antibodies, which exhibit efficient neutralization potential against pseudovirus carrying wild-type SARS-CoV-2. However, while wild-type and UK-N501Y pseudoviruses were similarly neutralized, those displaying SA-N501Y/K417N/E484K spike mutations moderately resist neutralization. Contribution of single or combined spike mutations to neutralization and infectivity were monitored, highlighting mechanisms by which viral infectivity and neutralization resistance are enhanced by N501Y or E484K/K417N mutations. Our study validates the importance of the Pfizer vaccine but raises concerns regarding its efficacy against specific SARS-CoV-2 circulating variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chom.2021.03.008

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 20

  1. ACTIV-3/TICO LY-CoV555 Study Group, 2021, A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, N Engl J Med, 384, 905, 10.1056/NEJMoa2033130 · DOI · Paper page
  2. Annavajhala, 2021, A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York, medRxiv
  3. Chan, 2020, The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody, bioRxiv
  4. Crawford, 2020, Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays, Viruses, 12, 10.3390/v12050513 · DOI · Paper page
  5. Giandhari, 2021, Early transmission of SARS-CoV-2 in South Africa: An epidemiological and phylogenetic report, Int. J. Infect. Dis., 103, 234, 10.1016/j.ijid.2020.11.128 · DOI
  6. Klasse, 2002, Occupancy and mechanism in antibody-mediated neutralization of animal viruses, J. Gen. Virol., 83, 2091, 10.1099/0022-1317-83-9-2091 · DOI · Paper page
  7. Krasnopolsky, 2020, Genome-wide CRISPR knockout screen identifies ZNF304 as a silencer of HIV transcription that promotes viral latency, PLoS Pathog., 16, e1008834, 10.1371/journal.ppat.1008834 · DOI
  8. Ku, 2021, Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape, Nat. Commun., 12, 469, 10.1038/s41467-020-20789-7 · DOI · Paper page
  9. Sabino, 2021, Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence, Lancet, 397, 452, 10.1016/S0140-6736(21)00183-5 · DOI · Paper page
  10. Santos, 2021, The high infectivity of SARS-CoV-2 B.1.1.7 is associated with increased interaction force between Spike-ACE2 caused by the viral N501Y mutation, bioRxiv
  11. Starr, 2020, Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding, Cell, 182, 1295, 10.1016/j.cell.2020.08.012 · DOI · Paper page
  12. Tegally, 2021, Sixteen novel lineages of SARS-CoV-2 in South Africa, Nat. Med., 27, 440, 10.1038/s41591-021-01255-3 · DOI · Paper page
  13. Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 183, 1735, 10.1016/j.cell.2020.11.032 · DOI · Paper page
  14. Walsh, 2020, Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, N. Engl. J. Med., 383, 2439, 10.1056/NEJMoa2027906 · doi:10.1056/nejmoa2027906 · Paper page
  15. Wang, 2020, A human monoclonal antibody blocking SARS-CoV-2 infection, Nat. Commun., 11, 2251, 10.1038/s41467-020-16256-y · DOI · Paper page
  16. West, 2021, SARS-CoV-2 lineage B.1.526 emerging in the New York region detected by software utility created to query the spike mutational landscape, bioRxiv
  17. Wu, 2020, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 368, 1274, 10.1126/science.abc2241 · DOI · Paper page
  18. Wu, 2021, mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants, bioRxiv
  19. Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 · DOI · Paper page
  20. Zhu, 2020, A Novel Coronavirus from Patients with Pneumonia in China, 2019, N. Engl. J. Med., 382, 727, 10.1056/NEJMoa2001017 · DOI · Paper page

Cited by

See all 179

Metadata

Authors
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Boehm-Cohen, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., & Taube, R.
Venue
Cell Host & Microbe
Publisher
Elsevier BV
Published
2021-04
Volume
29
Issue
4
Pages
522-528.e2
ISSN
1931-3128 (ISSN-L)
OpenAlex
W3136828643
Cited by
179
References
38
FWCI
13.55
Type
journal article
Language
en
Open access
bronze
Funders
  • Israel Science Foundation
  • Israel Ministry of Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. https://app.cochat.ai/papers/10.1016/j.chom.2021.03.008
The paper
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Boehm-Cohen, L., Raviv, Y., Shemer-Avni, Y., Rosenberg, E., & Taube, R. (2021). SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2021.03.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.